A handheld spirometry device, which can be used to anticipate breathing complications of Guillain-Barré syndrome
|Classification and external resources|
|eMedicine||emerg/222 neuro/7 pmr/48 neuro/598|
|Patient UK||Guillain–Barré syndrome|
Guillain–Barré syndrome (GBS, French pronunciation: [ɡiˈlɛ̃ baˈʁe], English pronunciation: //), also known as Guillain–Barré–Strohl syndrome or Landry's paralysis, is a rapid-onset muscle weakness as a result of damage to the peripheral nervous system. Many experience changes in sensation or develop pain, followed by muscle weakness beginning in the feet and hands. The symptoms develop over half a day to two weeks. During the acute phase, the disorder can be life-threatening with about a quarter developing weakness of the breathing muscles and requiring mechanical ventilation. Some are affected by changes in the function of the autonomic nervous system, which can lead to dangerous abnormalities in heart rate and blood pressure.
This autoimmune disease is caused by the body's immune system mistakenly attacking the peripheral nerves and damaging their myelin insulation. Sometimes this immune dysfunction is triggered by an infection. The diagnosis is usually made on based on the signs and symptoms, through the exclusion of alternative causes, and supported by tests such as nerve conduction studies and examination of the cerebrospinal fluid. Various classifications exist, depending on the areas of weakness, results of nerve conduction studies, and the presence of antiganglioside antibodies. It is classified as an acute polyneuropathy.
In those with severe weakness, prompt treatment with intravenous immunoglobulins or plasmapheresis, together with supportive care, will lead to good recovery in the majority. Some may experience ongoing difficulty with walking, painful symptoms, and some require long-term breathing support. Guillain–Barré syndrome is rare, at one to two cases per 100,000 people every year. The syndrome is named after the French neurologists Georges Guillain and Jean Alexandre Barré, who described it with André Strohl in 1916.
- 1 Signs and symptoms
- 2 Causes
- 3 Mechanism
- 4 Diagnosis
- 5 Treatment
- 6 Prognosis
- 7 Epidemiology
- 8 History
- 9 Research directions
- 10 See also
- 11 References
- 12 Further reading
- 13 External links
Signs and symptoms
The first symptoms of Guillain–Barré syndrome are numbness, tingling, and pain, alone or in combination. This is followed by weakness of the legs and arms that affects both sides equally and worsening over time. The weakness can take half a day to over two weeks to reach maximum severity, and then becomes steady. In one in five people the weakness continues to progress for as long as four weeks. The muscles of the neck may also be affected, and about half experience involvement of the cranial nerves, which supply the head and face; this may lead to weakness of the muscles of the face, swallowing difficulties and sometimes weakness of the eye muscles. In 8% the weakness affects only the legs (paraplegia or paraparesis). Involvement of the muscles that control the bladder and anus is unusual. In total, about a third of people with Guillain–Barré syndrome continue to be able to walk. Once the weakness has stopped progressing, it persists at a stable level ("plateau phase") before improvement occurs. The plateau phase can take between two days and six months, but the most common duration is a week. Pain-related symptoms affect more than half, and include back pain, painful tingling, muscle pain and pain in the head and neck relating to irritation of the lining of the brain.
Many people with Guillain–Barré syndrome have experienced the signs and symptoms of an infection in the 3–6 weeks prior to the onset of the neurological symptoms. This may consist of upper respiratory tract infection (rhinitis, sore throat) or diarrhea.
In children, particularly those younger than six years old, the diagnosis can be difficult and the condition is often initially mistaken (sometimes for up to two weeks) for other causes of pains and difficulty walking, such as viral infections, or bone and joint problems.
On neurological examination, characteristic features are the reduced power and reduced or absent tendon reflexes (hypo- or areflexia, respectively). However, a small proportion has normal reflexes in affected limbs before developing areflexia, and some may have exaggerated reflexes. In the "Miller Fisher variant" subtype of Guillain–Barré syndrome (see below), weakness of the eye muscles (ophthalmoplegia) is more pronounced and may occur together with abnormalities in coordination (ataxia). The level of consciousness is normally unaffected in Guillain–Barré syndrome, but the Bickerstaff brainstem encephalitis subtype may feature drowsiness, sleepiness, or coma.
A quarter of all people with Guillain–Barré syndrome develop weakness of the breathing muscles leading to respiratory failure, the inability to breathe adequately to maintain healthy levels of oxygen and/or carbon dioxide in the blood. This life-threatening scenario is complicated by other medical problems such as pneumonia, severe infections, blood clots in the lungs and bleeding in the digestive tract in 60% of those who require artificial ventilation.
The autonomic or involuntary nervous system, which is involved in the control of body functions such as heart rate and blood pressure, is affected in two thirds of people with Guillain–Barré syndrome, but the impact is variable. Twenty percent may experience severe blood pressure fluctuations and irregularities in the heart beat, sometimes to the point that the heart beat stops and requiring pacemaker-based treatment. Other associated problems are abnormalities in perspiration and changes in the reactivity of the pupils. Autonomic nervous system involvement can affect even those who do not have severe muscle weakness.
Two thirds of people with Guillain–Barré syndrome have experienced an infection before the onset of the condition. Most commonly these are episodes of gastroenteritis or a respiratory tract infection. In many cases the exact nature of the infection can be confirmed. Approximately 30% of cases are provoked by Campylobacter jejuni bacteria, which cause diarrhea. A further 10% cases are attributable to cytomegalovirus (CMV, HHV-5). Despite this, only very few people with Campylobacter or CMV infections develop Guillain–Barré syndrome (0.25–0.65 per 1000 and 0.6–2.2 per 1000 episodes, respectively). The strain of Campylobacter involved may determine the risk of GBS; different forms of the bacteria have different lipopolysaccharides on their surface, and some may induce illness (see below) while others will not.
Links between other infections and GBS are less certain. Two other herpesviruses (Epstein–Barr virus/HHV-4 and varicella zoster virus/HHV-3) and the bacterium Mycoplasma pneumoniae have been associated with GBS. The tropical viral infection dengue fever has been associated with episodes of GBS. Previous hepatitis E virus infection has been found to be more common in people with Guillain–Barré syndrome.
Some cases may be triggered by the influenza virus and potentially influenza vaccine. An increased incidence of Guillain–Barré syndrome followed influenza immunization that followed the 1976 swine flu outbreak (H1N1 A/NJ/76); 8.8 cases per million recipients developed the complication. Since then, close monitoring of cases attributable to vaccination has demonstrated that influenza itself can induce GBS. Small increases in incidence have been observed in subsequent vaccination campaigns, but not to the same extent. The 2009 flu pandemic vaccine (against pandemic swine flu virus H1N1/PDM09) did not cause a significant increase in cases. The benefits from vaccination to prevent influenza outweigh the small risks of GBS after vaccination. Even those who have previously experienced Guillain–Barré syndrome are considered safe to receive the vaccine in the future. Other vaccines, such as those against poliomyelitis, tetanus or measles, have not been associated with a risk of GBS.
The nerve dysfunction in Guillain–Barré syndrome is caused by an immune attack on the nerve cells of the peripheral nervous system and their support structures. The nerve cells have their body (the soma) in the spinal cord and a long projection (the axon) that carries electrical nerve impulses to the neuromuscular junction where the impulse is transferred to the muscle. Axons are wrapped in a sheath of Schwann cells that contain myelin. Between Schwann cells are gaps (nodes of Ranvier) where the axon is exposed. Different types of Guillain–Barré syndrome feature different types of immune attack. The demyelinating variant (AIDP, see below) features damage to the myelin sheath by white blood cells (T lymphocytes and macrophages); this process is preceded by activation of a group of blood proteins known as complement. In contrast, the axonal variant is mediated by IgG antibodies and complement against the cell membrane covering the axon without direct lymphocyte involvement.
Various antibodies directed at nerve cells have been reported in Guillain–Barré syndrome. In the axonal subtype, these antibodies have been shown to bind to gangliosides, a group of substances found in peripheral nerves. A ganglioside is a molecule consisting of ceramide bound to a small group of hexose-type sugars and containing various numbers of N-acetylneuraminic acid groups. The key four gangliosides against which antibodies have been described are GM1, GD1a, GT1a, and GQ1b, with different anti-ganglioside antibodies being associated with particular features; for instance, GQ1b antibodies have been linked with Miller Fisher variant GBS and related forms including Bickerstaff encephalitis. The production of these antibodies after an infection is probably the result of molecular mimicry, where the immune system is reacting to microbial substances but the resultant antibodies also react with substances occurring naturally in the body. After a Campylobacter infection, the body produces antibodies of the IgA class; only a small proportion of people also produce IgG antibodies against bacterial substance cell wall substances (e.g. lipooligosaccharides) that crossreact with human nerve cell gangliosides. It is not currently know how this process escapes central tolerance to gangliosides, which is meant to suppress the production of antibodies against the body's own substances. Not all antiganglioside antibodies cause disease, and it has recently been suggested that some antibodies bind to more than one type of epitope simultaneously (heterodimeric binding) and that this determines the response. Furthermore, the development of pathogenic antibodies may depend on the presence of ofter strains of bacteria in the bowel.
The diagnosis of Guillain–Barré syndrome depends on findings such as rapid development of muscle paralysis, absent reflexes, absence of fever, and a likely cause. Cerebrospinal fluid analysis (through a lumbar spinal puncture) and nerve conduction studies are supportive investigations commonly performed in the diagnosis of GBS. Testing for antiganglioside antibodies is often performed, but their contribution to diagnosis is usually limited. Blood tests are generally performed to exclude the possibility of another cause for weakness, such as a low level of potassium in the blood. An abnormally low level of sodium in the blood is often encountered in Guillain–Barré syndrome. This has been attributed to the inappropriate secretion of antidiuretic hormone, leading to relative retention of water.
In many cases, magnetic resonance imaging of the spinal cord is performed to distinguish between Guillain–Barré syndrome and other conditions causing limb weakness, such as spinal cord compression. If an MRI scan shows enhancement of the nerve roots, this may be indicative of GBS. In children, this feature is present in 95% of scans, but it is not specific to Guillain–Barré syndrome so other confirmation is also needed.
Cerebrospinal fluid (CSF) envelops the brain and the spine, and lumbar puncture is the removal of a small amount of fluid using a needle inserted between the lumbar vertebrae. A characteristic finding in Guillain–Barré syndrome is an elevated protein level with low numbers of white blood cells ("albuminocytological dissociation"); this distinguishes it from a number of other conditions (such as lymphoma and poliomyelitis) where both the protein and the cell count are elevated. Despite this, the CSF is unremarkable in 50% of people with Guillain–Barré syndrome in the first few days of symptoms, and 80% after the first week; therefore, normal results do not exclude the condition.
Repeating the lumbar puncture during the disease course is not recommended. The protein levels may rise after treatment has been administered.
Directly assessing nerve conduction of electrical impulses can exclude other causes of acute muscle weakness, as well as distinguish the different types of Guillain–Barré syndrome. Needle electromyography (EMG) and nerve conduction studies may be performed. In the first two weeks these investigations may not show any abnormality. Neurophysiology studies are not required for the diagnosis.
Formal criteria exist for each of the main subtypes of Guillain–Barré syndrome (AIDP and AMAN/AMSAN, see below), but these may misclassify some cases (particularly where there is reversible conduction failure) and therefore changes to these criteria have been proposed. Sometimes, repeat testing may be helpful.
A number of subtypes of Guillain–Barré syndrome are recognized. Despite this, many people have overlapping symptoms that can make the classification difficult in individual cases. All types have partial forms. For instance, some people experience only isolated eye movement or coordination problems; these are thought to be a subtype of Miller Fisher syndrome and have similar antiganglioside antibody patterns.
|Type||Symptoms||Population affected||Nerve conduction studies||Antiganglioside antibodies|
|Acute inflammatory demyelinating polyneuropathy (AIDP)||Sensory symptoms and muscle weakness, often with cranial nerve weakness and autonomic involvement||Most common in Europe and North America||Demyelinating polyneuropathy||No clear association|
|Acute motor axonal neuropathy (AMAN)||Isolated muscle weakness without sensory symptoms in less than 10%; cranial nerve involvement uncommon||Rare in Europe and North America, substantial proportion (30-65%) in Asia and Central and South America; sometimes called "Chinese paralytic syndrome"||Axonal polyneuropathy, normal sensory action potential||GM1a/b, GD1a & GalNac-GD1a|
|Acute motor and sensory axonal neuropathy (AMSAN)||Severe muscle weakness similar to AMAN but with sensory loss||-||Axonal polyneuropathy, reduced or absent sensory action potential||GM1, GD1a|
|Pharyngeal-cervical-brachial variant||Weakness particularly of the throat muscles, face, neck and shoulder muscles||-||Generally normal, sometimes axonal neuropathy in arms||Mostly GT1a, occasionally GQ1b, rarely GD1a|
|Miller Fisher syndrome||Ataxia, eye muscle weakness, areflexia but usually no limb weakness||This variant occurs more commonly in men than in women (2:1 ratio). Cases typically occur in the spring and the average age of occurrence is 43 years old.||Generally normal, sometimes discrete changes in sensory conduction or H-reflex detected||GQ1b, GT1a|
Other diagnostic entities are often included in the spectrum of Guillain–Barré syndrome. Bickerstaff's brainstem encephalitis, for instance, is part of the group of conditions now regarded as forms of Miller Fisher syndrome (anti-GQ1b antibody syndrome), as well as a related condition labelled "acute ataxic hypersomnolence" where coordination problems and drowsiness are present but no muscle weakness can be detected. BBE is characterized by the rapid onset of ophthalmoplegia, ataxia, and disturbance of consciousness, and may be associated with absent or decreased tendon reflexes and as well as Babinski's sign. The course of the disease is usually monophasic, but recurrent episodes have been reported. MRI abnormalities in the brainstem have been reported in 11%.
Whether isolated acute sensory loss can be regarded as a form of Guillain–Barré syndrome is a matter of dispute; this is a rare occurrence compared to GBS with muscle weakness but no sensory symptoms.
Plasmapheresis and intravenous immunoglobulins (IVIg) are the two main immunotherapy treatments for GBS. Plasmapheresis attempts to reduce the body's attack on the nervous system by filtering antibodies out of the bloodstream. Similarly, administration of IVIg neutralizes harmful antibodies and inflammation. These two treatments are equally effective and a combination of the two is not significantly better than either alone. Plasmapheresis speeds recovery when used within four weeks of the onset of symptoms. IVIg works as well as plasmapheresis when started within two weeks of the onset of symptoms, and has fewer complications. IVIg is usually used first because of its ease of administration and safety. Its use is not without risk; occasionally it causes liver inflammation, or in rare cases, kidney failure. Glucocorticoids alone have not been found to be effective in speeding recovery and could potentially delay recovery.
Respiratory failure may require intubation of the windpipe and breathing support through mechanical ventilation, generally on an intensive care unit. The need for ventilatory support can be anticipated by measurement of two spirometry-based breathing tests: the forced vital capacity (FVC) and the negative inspiratory force (NIF). An FVC of less than 15 ml per kilogram body weight or an NIF of less than 60 cmH2O are considered markers of severe respiratory failure.
While pain is common in people with Guillain–Barré syndrome, studies comparing different types of pain medication are insufficient to make a recommendation as to which should be used.
Following the acute phase, around 40% of people require intensive rehabilitation with the help of a multidisciplinary team to focus on improving activities of daily living (ADLs). Studies into the subject have been limited, but it is likely that intensive rehabilitation improves long-term symptoms. Teams may include physical therapists, occupational therapists, social workers, psychologists, other allied health professionals and nurses. The team usually works under the supervision of a neurologist or rehabilitation physician directing treatment goals.
Physiotherapy interventions include strength, endurance and gait training with graduated increases in mobility, maintenance of posture and alignment as well as joint function. Occupational therapy aims to improve everyday function with domestic and community tasks as well as driving and work. Psychologists may provide counseling and support. Home modifications, gait aids, orthotics and splints may be provided. Speech-language pathology input may be required in those with speech and swallowing problems, as well as to support communication in those who require ongoing breathing support (often through a tracheostomy). Nutritional support may be provided by the team and by dietitians. Psychological interventions may be required for anxiety, fear and depression.
Guillain–Barré syndrome can lead to death as a result of a number of complications: severe infections, blood clots, and cardiac arrest likely due to autonomic neuropathy. Despite optimum care this occurs in about 5% of cases.
There is a variation in the rate and extent of recovery. The prognosis of Guillain–Barré syndrome is determined mainly by age (those over 40 may have a poorer outcome), and by the severity of symptoms after two weeks. Furthermore, those who experienced diarrhea before the onset of disease have a worse prognosis. On the nerve conduction study, the presence of conduction block predicts poorer outcome at 6 months. In those who have received intravenous immunoglobulins, a smaller increase in IgG in the blood two weeks after administration is associated with poorer mobility outcomes at six months than those whose IgG level increased substantially. If the disease continues to progress beyond four weeks, or there are multiple fluctuations in the severity (more than two in eight weeks), the diagnosis may be chronic inflammatory demyelinating polyneuropathy which is treated differently.
In research studies, the outcome from an episode of Guillain–Barré syndrome is recorded on a scale from 0-6, where 0 denotes completely healthy, 1 very minor symptoms but able to run, 2 able to walk but not to run, 3 requiring a stick or other support, 4 confined to bed or chair, 5 requiring long-term respiratory support, 6 death.
The health-related quality of life (HRQL) after an attack of Guillain–Barré syndrome can be significantly impaired. About a fifth are unable to walk unaided after six months, and many experience chronic pain, fatigue and difficulty with work, education, hobbies and social activities. HRQL improves significantly in the first year.
In Western countries, the number of new episodes per year has been estimated to be between 0.89 and 1.89 cases per 100,000 people. Children and young adults are less likely to be affected than the elderly: the risk increases by 20% for every decade of life. Men are more likely to develop Guillain–Barré syndrome than women; the relative risk for men is 1.78 compared to women.
The distribution of subtypes varies between countries. In Europe and the United States, 60–80% of people with Guillain–Barré syndrome have the demyelinating subtype (AIDP), and AMAN affects only a small number (6–7%). In Asia and Central and South America, that proportion is significantly higher (30–65%). This may be related to the exposure to different kinds of infection, but also the genetic characteristics of that population. Miller Fisher variant is thought to be more common in Southeast Asia.
French physician Jean-Baptiste Octave Landry first described the disorder in 1859. In 1916, Georges Guillain, Jean Alexandre Barré, and André Strohl diagnosed two soldiers with the illness and described the key diagnostic abnormality—albuminocytological dissociation—of increased spinal fluid protein concentration but a normal cell count.
Canadian neurologist C. Miller Fisher described the variant that bears his name in 1956. British neurologist Edwin Bickerstaff, based in Birmingham, described the brainstem encephalitis type in 1951 with Philip Cloake, and made further contributions with another paper in 1957. Guillain had reported on some of these features prior to their full description in 1938. Further subtypes have been described since then, such as the form featuring pure ataxia and the type causing pharyngeal-cervical-brachial weakness. The axonal subtype was first described in the 1990s.
Diagnostic criteria were developed in the late 1970s after the series of cases associated with swine flu vaccination. These were refined in 1990. The case definition was revised by the Brighton Collaboration for vaccine safety in 2009, but is mainly intended for research. Plasma exchange was first used in 1978 and its benefit confirmed in larger studies in 1985. Intravenous immunoglobulins were introduced in 1988, and its non-inferiority compared to plasma exchange was demonstrated in studies in the early 1990s.
The understanding of the disease mechanism of Guillain–Barré syndrome has evolved in recent years. Development of new treatments has been limited since immunotherapy was introduced in the 1980s and 1990s. Current research is aimed at demonstrating whether some people who have received IVIg might benefit from a second course if the antibody levels measured in blood after treatment have only shown a small increase. Studies of the immunosuppressive drug mycophenolate mofetil, brain-derived neurotrophic factor and interferon beta (IFN-β) have not demonstrated benefit to support their widespread use.
An animal model (experimental autoimmune neuritis in rats) is often used for studies, and some agents have shown promise: glatiramer acetate, quinpramine, fausadil (an inhibitor of the Rho-kinase enzyme), and the heart drug flecainide. An antibody targeted against the anti-GD3 antiganglioside antibody has shown benefit in laboratory research. Given the role of the complement system in GBS, it has been suggested that complement inhibitors (such as the drug eculizumab) may be effective.
- Yuki, Nobuhiro; Hartung, Hans-Peter (14 June 2012). "Guillain–Barré Syndrome". New England Journal of Medicine 366 (24): 2294–2304. doi:10.1056/NEJMra1114525. PMID 22694000.
- van den Berg, Bianca; Walgaard, Christa; Drenthen, Judith; Fokke, Christiaan; Jacobs, Bart C.; van Doorn, Pieter A. (15 July 2014). "Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis". Nature Reviews Neurology 10 (8): 469–482. doi:10.1038/nrneurol.2014.121. PMID 25023340.
- Ryan, Monique M. (December 2013). "Pediatric Guillain-Barré syndrome". Current Opinion in Pediatrics 25 (6): 689–693. doi:10.1097/MOP.0b013e328365ad3f. PMID 24240288.
- van Doorn, Pieter A; Ruts, Liselotte; Jacobs, Bart C (October 2008). "Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome". The Lancet Neurology 7 (10): 939–950. doi:10.1016/S1474-4422(08)70215-1. PMID 18848313.
- Shahrizaila, N.; Yuki, N. (15 September 2012). "Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome". Journal of Neurology, Neurosurgery & Psychiatry 84 (5): 576–583. doi:10.1136/jnnp-2012-302824. PMID 22984203.
- van Doorn PA, Kuitwaard K, Walgaard C, et al. (May 2010). "IVIG treatment and prognosis in Guillain-Barré syndrome". Journal of Clinical Immunology. 30 Suppl 1: S74–8. doi:10.1007/s10875-010-9407-4. PMC 2883091. PMID 20396937.
- Carod-Artal FJ, Wichmann O, Farrar J, Gascón J (September 2013). "Neurological complications of dengue virus infection". The Lancet Neurology 12 (9): 906–19. doi:10.1016/S1474-4422(13)70150-9. PMID 23948177.
- Eldar AH, Chapman J (April 2014). "Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification". Autoimmunity Reviews 13 (4-5): 525–30. doi:10.1016/j.autrev.2014.01.033. PMID 24434363.
- Lehmann HC, Hartung HP, Kieseier BC, Hughes RA (Sep 2010). "Guillain-Barré syndrome following influenza vaccination". The Lancet Infectious Diseases 10 (9): 643–51. doi:10.1016/S1473-3099(10)70140-7. PMID 20797646.
- Rinaldi, Simon (June 2013). "Update on Guillain-Barré syndrome". Journal of the Peripheral Nervous System 18 (2): 99–112. doi:10.1111/jns5.12020. PMID 23781958.
- Kuwabara S, Yuki N (December 2013). "Axonal Guillain-Barré syndrome: concepts and controversies". The Lancet Neurology 12 (12): 1180–8. doi:10.1016/S1474-4422(13)70215-1. PMID 24229616.
- Willison, Hugh J.; Goodyear, Carl S. (September 2013). "Glycolipid antigens and autoantibodies in autoimmune neuropathies". Trends in Immunology 34 (9): 453–459. doi:10.1016/j.it.2013.05.001. PMID 23770405.
- Spasovski G, Vanholder R, Allolio B, et al. (25 Feb 2014). "Clinical practice guideline on diagnosis and treatment of hyponatraemia". European Journal of Endocrinology 170 (3): G1–47. doi:10.1530/EJE-13-1020.
- Uncini A, Kuwabara S (August 2012). "Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update". Clinical Neurophysiology 123 (8): 1487–95. doi:10.1016/j.clinph.2012.01.025. PMID 22480600.
- Wakerley BR, Uncini A, Yuki N; GBS Classification Group (September 2014). "Guillain-Barré and Miller Fisher syndromes--new diagnostic classification". Nature Reviews Neurology. 10 (9): 537–44. doi:10.1038/nrneurol.2014.138. PMID 25072194.
- Mori M, Kuwabara S, Yuki N (January 2012). "Fisher syndrome: clinical features, immunopathogenesis and management". Expert Rev Neurother 12 (1): 39–51. doi:10.1586/ern.11.182. PMID 22149656.
- Hughes, RA; Swan, AV; van Doorn, PA (Sep 19, 2014). "Intravenous immunoglobulin for Guillain-Barré syndrome.". The Cochrane Database of Systematic Reviews 9: CD002063. doi:10.1002/14651858.CD002063.pub6. PMID 25238327.
- Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC (September 2003). "Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology 61 (6): 736–40. doi:10.1212/WNL.61.6.736. PMID 14504313.
- Dantal J (October 2013). "Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk". American Journal of Nephrology 38 (4): 275–84. doi:10.1159/000354893. PMID 24051350.
- Hughes, RA; van Doorn, PA (15 August 2012). "Corticosteroids for Guillain-Barré syndrome.". The Cochrane Database of Systematic Reviews 8: CD001446. doi:10.1002/14651858.CD001446.pub4. PMID 22895921.
- Dimachkie MM, Barohn RJ (May 2013). "Guillain-Barré syndrome and variants". Neurology Clinics 31 (2): 491–510. doi:10.1016/j.ncl.2013.01.005. PMC 3939842. PMID 23642721.
- Liu, J; Wang, LN; McNicol, ED (20 October 2013). "Pharmacological treatment for pain in Guillain-Barré syndrome.". The Cochrane Database of Systematic Reviews 10: CD009950. doi:10.1002/14651858.CD009950.pub2. PMID 24142399.
- Khan, F.; Amatya, B. (September 2012). "Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review.". European journal of physical and rehabilitation medicine 48 (3): 507–22. PMID 22820829.
- Khan, F; Ng, L; Amatya, B; Brand, C; Turner-Stokes, L (6 October 2010). "Multidisciplinary care for Guillain-Barré syndrome.". The Cochrane database of systematic reviews (10): CD008505. doi:10.1002/14651858.CD008505.pub2. PMID 20927774.
- Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA (Sep 2007). "Immunotherapy for Guillain-Barré syndrome: a systematic review". Brain 130: 2245–57. doi:10.1093/brain/awm004. PMID 17337484.
- Darweesh, Sirwan K. L.; Polinder, Suzanne; Mulder, Maxim J. H. L.; Baena, Cristina P.; van Leeuwen, Nikki; Franco, Oscar H.; Jacobs, Bart C.; van Doorn, Pieter A. (March 2014). "Health-related quality of life in Guillain-Barré syndrome patients: a systematic review". Journal of the Peripheral Nervous System 19 (1): 24–35. doi:10.1111/jns5.12051. PMID 24456426.
- Sejvar, James J.; Baughman, Andrew L.; Wise, Matthew; Morgan, Oliver W. (2011). "Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis". Neuroepidemiology 36 (2): 123–133. doi:10.1159/000324710. PMID 21422765.
- Goetz, C. G. (1 May 1998). "Georges Guillain's neurologic exploration of America". Neurology 50 (5): 1451–1455. doi:10.1212/WNL.50.5.1451. PMID 9596004.
- Landry, Jean-Baptiste (1859). "Note sur la paralysie ascendante aiguë". Gazette Hebdomadaire de Médecine et de Chirurgie 6: 472–474, 486–488.
- Guillain, G.; Barré, J.; Strohl, A. (1916). "Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire. Remarques sur les caractères cliniques et graphiques des réflexes tendineux". Bulletins et mémoires de la Société des Médecins des Hôpitaux de Paris 40: 1462–70.
- Fisher M (1956). "An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmolplegia, ataxia and areflexia)". N. Engl. J. Med. 255 (2): 57–65. doi:10.1056/NEJM195607122550201. PMID 13334797.
- Bickerstaff, E.R.; Cloake, P.C. (14 July 1951). "Mesencephalitis and rhombencephalitis.". British Medical Journal 2 (4723): 77–81. doi:10.1136/bmj.2.4723.77. PMC 2069534. PMID 14848512.
- Bickerstaff, E.R. (15 June 1957). "Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis.". British Medical Journal 1 (5032): 1384–7. doi:10.1136/bmj.1.5032.1384. PMC 1973653. PMID 13436795.
- Asbury, Arthur K.; Cornblath, David R. (1990). "Assessment of current diagnostic criteria for Guillain-Barré syndrome.". Annals of Neurology. 27 Suppl: S21–4. doi:10.1002/ana.410270707. PMID 2194422.
- Sejvar, James J.; Kohl, Katrin S.; Gidudu, Jane; Amato, Anthony; Bakshi, Nandini; Baxter, Roger; Burwen, Dale R.; Cornblath, David R.; Cleerbout, Jan; Edwards, Kathryn M.; Heininger, Ulrich; Hughes, Richard; Khuri-Bulos, Najwa; Korinthenberg, Rudolf; Law, Barbara J.; Munro, Ursula; Maltezou, Helena C.; Nell, Patricia; Oleske, James; Sparks, Robert; Velentgas, Priscilla; Vermeer, Patricia; Wiznitzer, Max (January 2011). "Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data". Vaccine 29 (3): 599–612. doi:10.1016/j.vaccine.2010.06.003. PMID 20600491.
- Walgaard, Christa; Jacobs, Bart C; van Doorn, Pieter A (March 2011). "Emerging drugs for Guillain-Barré syndrome". Expert Opinion on Emerging Drugs 16 (1): 105–120. doi:10.1517/14728214.2011.531699. PMID 21352072.
- Steinberg, Gareth J. Parry, Joel S. (2006). Guillain-Barré syndrome: from diagnosis to recovery (American Academy of Neurology). New York, N.Y.: Pub Group West. ISBN 978-1932603569.